[Retinopathy of prematurity]

C Jandeck1, U Kellner, M H Foerster

  • 1Universitätsaugenklinik Charité - Universitätsmedizin Berlin, Berlin. claudia.jandeck@charite.de

Klinische Monatsblatter Fur Augenheilkunde
|March 31, 2004
PubMed

Insights

Retinopathy of prematurity (ROP) remains a significant concern despite advances in neonatal care. Early ophthalmologic screening and timely laser treatment for advanced ROP are crucial for preventing blindness in premature infants.

Area of Science:

  • Ophthalmology
  • Neonatology
  • Pediatric Medicine

Context:

  • Premature infants face significant risks for vision impairment, particularly retinopathy of prematurity (ROP).
  • Advances in neonatal intensive care have increased survival rates of extremely premature infants, but ROP incidence remains high.
  • ROP is a leading cause of preventable childhood blindness globally.

Purpose:

  • To review current knowledge and recent clinical advances in retinopathy of prematurity (ROP).
  • To discuss the pathophysiology, classification, and epidemiology of ROP.
  • To summarize treatment strategies, outcomes, and future therapeutic options for ROP.

Summary:

  • This review covers the history, classification, and pathophysiology of ROP.
  • It summarizes findings from multicenter treatment trials and discusses current screening guidelines (German and international).
  • Therapeutic strategies, treatment outcomes, and potential future therapies like anti-angiogenic factors are explored.

Impact:

  • Highlights the importance of timely ophthalmologic screening and laser treatment in preventing ROP-related blindness.
  • Addresses the long-term ophthalmologic sequelae in preterm infants, including amblyopia, strabismus, and refractive errors.
  • Informs clinical practice and research directions for managing and potentially preventing retinopathy of prematurity.